TriSalus Life Sciences, Inc.

For the period ended Mar 31, 2026. Filed May 12, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 12, 2026

TLSI$3.25-7.9%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(unaudited, in thousands, except share and per share data)

	Three Months Ended
	March 31, 2026	March 31, 2025
Revenue	$8,899	$9,167
Cost of goods sold	1,230	1,495
Gross profit	7,669	7,672
Operating expenses:
Research and development (1)	3,216	3,021
Sales and marketing	7,413	6,734
General and administrative (1)	5,451	5,246
Loss from operations	(8,411)	(7,329)
Other income (expense)
Interest income	164	74
Interest expense	(1,436)	(1,209)
Change in fair value of SEPA, warrant and revenue base redemption liabilities	3,900	(835)
Change in fair value of contingent earnout liability	7,402	(820)
Other expense, net	(76)	(251)
Income (loss) before income taxes	1,543	(10,370)
Income tax expense	(4)	(5)
Net income (loss)	$1,539	$(10,375)
Undeclared dividends on Series A Preferred Stock	—	(712)
Net income (loss) attributable to common stockholders	$1,539	$(11,087)
Basic earnings (loss) per share	$0.03	$(0.39)
Diluted earnings (loss) per share	$0.03	$(0.39)
Weighted average common shares outstanding, basic	51,539,682	28,527,453
Weighted average common shares outstanding, diluted	52,314,410	28,527,453
(1)Amounts presented in the quarter ended March 31, 2025 have been revised to align expense classification for the 2025 fiscal year period.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.